Elixirgen Therapeutics, LLC

Elixirgen Therapeutics specializes in developing innovative biotechnological solutions aimed at addressing rare diseases and age-related conditions through advanced therapies and gene delivery technologies. Elixirgen Therapeutics is focused on biotechnology for the treatment of rare diseases and aging-related conditions. The company was founded in 2017 in Baltimore, US by Minoru Ko, with Akihiro Ko serving as CEO. Elixirgen received USD 4 mn in Series A financing in June 2018 from The University of Tokyo Edge Capital Partners, marking its first investment round.

This funding aims to facilitate the development of their therapeutic candidates and enhance operational capabilities. Elixirgen Therapeutics specializes in advanced biotechnological products aimed at treating rare diseases and aging-associated conditions. The company's primary offerings include ZSCAN4 and Bobcat® mRNA technologies, which are designed to address significant unmet medical needs. ZSCAN4 focuses on extending telomeres through a telomerase-independent mechanism, targeting conditions such as Telomere Biology Disorders, myelodysplastic syndromes (MDS), and idiopathic pulmonary fibrosis (IPF).

Bobcat® mRNA serves as a gene therapy vector capable of delivering large genetic payloads, including the full-length dystrophin protein for patients with Duchenne muscular dystrophy (DMD). These innovations are currently under clinical evaluation, with ZSCAN4 undergoing Phase I/II trials at Cincinnati Children’s Hospital Medical Center. Elixirgen primarily serves hospitals, research institutions, and specialized clinics in North America and select international markets, where the end-users are typically patients suffering from rare genetic disorders. Elixirgen Therapeutics generates revenue through partnerships and clinical collaborations rather than direct consumer sales.

The company is involved in strategic partnerships with healthcare institutions and biopharmaceutical companies to further develop and commercialize its therapeutic candidates, which include proprietary products such as EXG-34217 for Telomere Biology Disorders and EXG-7001 targeting DMD. Transactions typically occur within the framework of clinical trial agreements, research collaborations, or licensing agreements, where partner organizations may contribute funding in exchange for access to Elixirgen's advancing technologies. These partnerships aid in covering development costs while simultaneously facilitating the pathway to eventual commercialization of their therapies. Specific pricing structures for individual products or services have not been disclosed, reflecting the early-stage nature of the company's offerings in the biotechnology sector.

Elixirgen Therapeutics plans to utilize the capital raised in their Series A funding to advance the development of its leading therapies, including ZSCAN4 and Bobcat® mRNA. The company is focusing on expanding its clinical trials and aims to launch new products targeting rare genetic disorders within the next few years. Geographic expansion into international markets, particularly in Europe and Asia, is also a critical goal, with a target timeline set for the next two to three years to enhance their market presence. The resources from the recent financing will support research and development initiatives, facilitating further advancements in their therapeutic offerings.